Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Amaia Cadinanos Garai"'
Autor:
Harry Dolstra, Claire Roddie, Martin A Pule, Vedika Mehra, Giulia Agliardi, Juliana Dias Alves Pinto, Manar S Shafat, Amaia Cadinanos Garai, Louisa Green, Alastair Hotblack, Fred Arce Vargas, Karl S Peggs, Anniek B van der Waart
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss 9 (2023)
Background AUTO1 is a fast off-rate CD19-targeting chimeric antigen receptor (CAR), which has been successfully tested in adult lymphoblastic leukemia. Tscm/Tcm-enriched CAR-T populations confer the best expansion and persistence, but Tscm/Tcm number
Externí odkaz:
https://doaj.org/article/304fa86b5512400a84f30e4d82b38677
Autor:
Karl S. Peggs, Bilyana Popova, Claire Roddie, David Irvine, Marina Mitsikakou, Martin Pule, Joanna Olejnik, Graham M. Wheeler, Maria A. V. Marzolini, Mark W. Lowdell, Farzin Farzaneh, Amaia Cadinanos-Garai, Sabine Domning, Harriet Roddy, Victoria J. Spanswick, Ketki Vispute, Leigh Wood, Juliana Dias, Leticia Bosshard-Carter, David C. Linch, John A. Hartley, Maeve A O'Reilly, Adrian Bloor, Mahnaz Abbasian, Vedika Mehra, Laura Clifton-Hadley, Helen Lowe
Publikováno v:
Journal of Clinical Oncology. 39:3352-3363
PURPOSE Prognosis for adult B-cell acute lymphoblastic leukemia (B-ALL) is poor, and there are currently no licensed CD19 chimeric antigen receptor (CAR) therapeutics. We developed a novel second-generation CD19-CAR (CAT19-41BB-Z) with a fast off rat
Autor:
Martin Pule, Farzin Farzaneh, Maeve A O'Reilly, Bilyana Popova, Louisa Green, William R. Wilson, Marina Mitsikakou, Helen Lowe, Maria A V Marzolini, John A. Hartley, Claire Roddie, Mark W. Lowdell, Vitoria Meyer Cantinho Pereira, Victoria J. Spanswick, Leigh Wood, Joanna Olejnik, Yenting Ngai, Mhairi Vaughan, David C. Linch, Leah Ensell, Amaia Cadinanos Garai, Juliana Dias, Karl S. Peggs, Mahnaz Abbasian
Publikováno v:
Blood. 138:3823-3823
INTRODUCTION We have previously described AUTO1, a CD19 CAR with a fast off-rate CD19 binding domain, designed to reduce CAR-T immune toxicity and improve engraftment. Its clinical activity has been tested in r/r paediatric and adult B-ALL. Cumulativ
Autor:
Farhatullah Syed, David C. Linch, Joanna Olejnik, Yashma Pathak, Victoria J. Spanswick, Mark W. Lowdell, John A. Hartley, Farzin Farzaneh, Leigh Wood, Maeve A O'Reilly, Claire Roddie, Helen Lowe, Maria A V Marzolini, Laura Clifton-Hadley, Bilyana Popova, Waseem Qasim, Graham M. Wheeler, Martin Pule, Leticia Bosshard, Juliana Dias, Karl S. Peggs, Mahnaz Abbasian, Amaia Cadinanos Garai
Publikováno v:
Blood. 136:3-4
Introduction: Prognosis for adult B-cell Acute Lymphoblastic Leukaemia (B-ALL) is poor and there is currently no licensed CD19 Chimeric Antigen Receptor (CAR) therapeutic. We developed a novel CD19 CAR (CAT-41BBz CAR) with a fast off-rate, designed t